Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Rexahn Pharmaceuticals Inc (REXN) Com Stk USD0.0001

Sell:$1.98 Buy:$3.10 Change: $0.06 (2.86%)
Market closed |  Prices as at close on 23 September 2020 | Switch to live prices |
Change: $0.06 (2.86%)
Market closed |  Prices as at close on 23 September 2020 | Switch to live prices |
Change: $0.06 (2.86%)
Market closed |  Prices as at close on 23 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's pipeline features two clinical stage oncology product candidates and additional compounds in preclinical development. Its pipeline includes RX-3117, RX-5902 and RX-0301. RX-3117 is an investigational oral small molecule nucleoside compound. RX-5902 is a potential small molecule modulator of the Wnt/beta-catenin pathway, which plays a role in cancer cell proliferation and tumor growth. RX-5902 modulates the pathway through inhibition of phosphorylated p68, a protein that helps to transport beta-catenin from the cytoplasm into the cell nucleus. RX-0301 is being developed as a nano-liposomal formulation of RX-0201, an antisense oligonucleotide compound that is complementary to mRNA coding for Akt-1.

Contact details

15245 Shady Grove Rd Ste 455
United States
+1 (240) 2685300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$9.25 million
Shares in issue:
4.43 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Peter Brandt
    Independent Chairman of the Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.